Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 125mg;  ;   - dispersible tablet - 125 mg - active: deferasirox 125mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 250mg;  ;   - dispersible tablet - 250 mg - active: deferasirox 250mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 500mg;  ;   - dispersible tablet - 500 mg - active: deferasirox 500mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox -

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

bayer new zealand limited - levonorgestrel 75mg (micronised) - subcutaneous implant - 150 mg - active: levonorgestrel 75mg (micronised) excipient: dow corning qcf-7-4910 dimethylsiloxane/methylvinylsiloxane external tubing (373-tw) polysiloxane adhesive type a - long-term contraception

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

jade-euro-med -

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

jade-euro-med -